Metsera: Funding, Investors & Team (Sep 2026)
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.
Metsera has raised $215M across 1 funding round on record, the most recent a Series B of $215M announced in Nov 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Metsera Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Metsera Funding Rounds
Metsera Founders and Leadership Team
Contact details for the Metsera team: 1 of 1 has an email address on file.
Start 14-day free trial →Metsera Funding Compared to Other Biotechnology Startups
Metsera's latest round of $215M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Metsera in Biotechnology and New York
Companies Similar to Metsera
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Metsera Funding FAQs
What does Metsera do?
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.
How much funding has Metsera raised?
Metsera has raised $215M across 1 round on record. The most recent is a Series B of $215M announced in Nov 2024.
When did Metsera last raise funding?
Metsera's most recent funding round on record is a Series B of $215M, announced in Nov 2024.
Who founded Metsera?
FundedIQ lists Whit Bernard (Founder) at Metsera.
Where is Metsera headquartered?
Metsera is based in New York, United States.
How many employees does Metsera have?
Metsera is in the 11-50 employee band.
How does Metsera's funding compare to other Biotechnology startups?
Metsera's latest round of $215M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Metsera Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Metsera is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.